Systemic Sclerosis trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Systemic Sclerosis. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month2 studies across 2 companies, in the next 180 days.
January 2027 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)NCT05925803Number of participants responding to treatment based on the Revised Composite Response Index in Systemic Sclerosis (CRISS-25) | Phase 3 | Active, not recruiting | 2027-01-06 | in 139 d | 2026-07-23 |
| TCRX | TScan Therapeutics, Inc. | A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune DiseaseNCT06587828observationalIdentify peptide targets together with their associated TCRs in patients with autoimmune diseases under study. | — | Recruiting | Jan 2027 | ≤ 164 d | 2025-11-24 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Systemic Sclerosis
most recently updated first31 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CABA | Cabaletta Bio | $493M | RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic SclerosisNCT06328777Phase 1/2: To evaluate incidence of adverse events | Phase 2/3 | Recruiting | Biological: CABA-201, CABA-201 | Systemic Sclerosis, Scleroderma, Interstitial Lung Diseases | 37 | 2024-07-02 | Jul 2029 | ≤ 1,076 d | 2026-08-17 |
| NKTX | Nkarta, Inc. | $173M | A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)NCT06733935Incidence of Dose-limiting toxicities (DLTs) [Safety and Tolerability] | Phase 1/2 | Recruiting | Drug: NKX019, Fludarabine, Cyclophosphamide | Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis | 240 | 2024-11-04 | Oct 2028 | ≤ 803 d | 2026-08-07 |
| CRSP | CRISPR Therapeutics | $5.1B | A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune DiseaseNCT06925542To evaluate the safety of CTX112 in adult subjects with refractory autoimmune diseases, including SLE, SSc or IIM | Phase 1 | Recruiting | Biological: CTX112 | SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis | 80 | 2025-03-10 | 2031-12-31 | in 1,959 d | 2026-08-07 |
| XNCR | Xencor, Inc. | $1.9B | A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune DiseasesNCT07284797Percentage of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) | Phase 1 | Recruiting | Biological: XmAb657 | Healthy, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjögren's Disease | 60 | 2026-02-24 | Oct 2028 | ≤ 803 d | 2026-08-03 |
| ARTV | Artiva Biotherapeutics, Inc. | $571M | AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.NCT06991114Safety | Phase 2 | Recruiting | Drug: Allogeneic NK Cells | Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease | 90 | 2025-07-09 | Jan 2028 | ≤ 529 d | 2026-07-31 |
| ALLO | Allogene Therapeutics | $701M | A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune DiseaseNCT07085104Incidence of Dose Limiting toxicities (DLTs) and Other Safety Parameters | Phase 1 | Recruiting | Genetic: ALLO-329 · Drug: Cyclophosphamide, Fludarabine | Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis | 66 | 2025-11-13 | Feb 2028 | ≤ 558 d | 2026-07-31 |
| AZN | AstraZeneca | — | A Study of AZD0120 in Autoimmune DiseasesNCT07295847Number of participants and severity of dose limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs) | Phase 1 | Recruiting | Biological: AZD0120 | Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis | 27 | 2026-01-09 | 2028-02-22 | in 551 d | 2026-07-28 |
| AZN | AstraZeneca | — | Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)NCT05925803Number of participants responding to treatment based on the Revised Composite Response Index in Systemic Sclerosis (CRISS-25) | Phase 3 | Active, not recruiting | Combination product: Anifrolumab (blinded), Anifrolumab (unblinded, open label) · Drug: Placebo (blinded) | Systemic Sclerosis, Scleroderma | 314 | 2023-11-08 | 2027-01-06 | in 139 d | 2026-07-23 |
| ZURA | Zura Bio Inc | $553M | Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)NCT06843239[Period 1] Change from baseline in modified Rodnan Skin Score (mRSS) at 24 weeks | Phase 2 | Active, not recruiting | Biological: Tibulizumab · Other: Placebo | Systemic Sclerosis (SSc), Scleroderma | 80 | 2025-02-06 | May 2027 | ≤ 284 d | 2026-07-20 |
| FATE | Fate Therapeutics | $307M | A Phase 1 Study of FT819 in B-cell Mediated Autoimmune DiseaseNCT06308978Number of participants with treatment-emergent adverse events (TEAEs) | Phase 1 | Recruiting | Drug: FT819, Fludarabine, Cyclophosphamide, Bendamustine | Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Lupus Nephritis | 244 | 2024-03-28 | 2027-09-30 | in 406 d | 2026-05-22 |
| CPIX | Cumberland Pharmaceuticals | $114M | Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial HypertensionNCT02682511Incidence of adverse events (AEs) and Serious AEs (SAEs) | Phase 2 | Active, not recruiting | Drug: Oral Ifetroban, Oral Placebo | Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases | 34 | Jan 2017 | Jun 2026 | — | 2026-04-15 |
| AMGN | Amgen | $229.9B | A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic SclerosisNCT04781543results2026-03-20Change From Baseline in Forced Vital Capacity Percent (FVC%) Predicted at Week 52 | Phase 2 | Terminatedsponsor's stated reason: The study was terminated due to meeting pre-defined criteria for futility. | Drug: HZN-825 BID, Placebo, HZN-825 QD | Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | 301 | 2021-11-05 | 2025-02-24actual | — | 2026-03-20 |
| KYTX | Kyverna Therapeutics | $526M | A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101NCT07403188observationalNumber of participants with treatment-related adverse events (AEs) as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU). | — | Recruiting | Drug: KYV-101 | Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA), Multiple Sclerosis, Dermatomyositis, Systemic Sclerosis (SSc) | 70 | 2025-11-24 | Jan 2041 | ≤ 5,278 d | 2026-02-11 |
| IPSC | Century Therapeutics, Inc. | $353M | A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune DiseasesNCT06255028Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEs | Phase 1 | Active, not recruiting | Biological: CNTY-101, IL-2 · Drug: Lymphodepleting Chemotherapy | Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis | 6 | 2025-02-06 | Aug 2028 | ≤ 742 d | 2026-01-08 |
| AMGN | Amgen | $229.9B | An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)NCT05626751results2026-01-05Change From Baseline in Forced Vital Capacity Percentage (FVC%) Predicted at Week 52 | Phase 2 | Terminatedsponsor's stated reason: The study was not stopped due to safety reasons | Drug: HZN-825 | Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | 174 | 2022-11-04 | 2025-02-24actual | — | 2026-01-05 |
| TCRX | TScan Therapeutics, Inc. | $107M | A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune DiseaseNCT06587828observationalIdentify peptide targets together with their associated TCRs in patients with autoimmune diseases under study. | — | Recruiting | Procedure: Companion blood samples with procedure | Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma, Ankylosing Spondylitis, Celiac Disease, Non-radiographic Axial Spondyloarthritis (Nr-axSpA), Crohn&Amp;#39;s Disease, Birdshot Chorioretinitis | 300 | 2023-01-03 | Jan 2027 | ≤ 164 d | 2025-11-24 |
| KYTX | Kyverna Therapeutics | $526M | KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic SclerosisNCT06400303Incidence of adverse events and laboratory abnormalities (Phase 1) | Phase 1/2 | Active, not recruiting | Biological: KYV-101 · Drug: Standard lymphodepletion regimen | Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria | 3 | 2024-08-06 | Mar 2026 | — | 2025-10-08 |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.4B | A Study of KHK4827 in Patients With Systemic SclerosisNCT04368403serum KHK4827 concentration | Phase 1 | Completed | Drug: KHK4827 | Systemic Sclerosis | 8 | 2017-10-06 | 2019-01-31actual | — | 2025-07-11 |
| AMGN | Amgen | $229.9B | A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and DermatomyositisNCT03817424Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Phase 1 | Completed | Drug: VIB7734, Placebo | Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, Dermatomyositis | 31 | 2018-12-13 | 2020-07-20actual | — | 2024-12-13 |
| BMY | Bristol-Myers Squibb | $134.9B | Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic SclerosisNCT03831438Primary Outcome: Incidence of treatment related adverse events | Phase 1 | Completed | Drug: AVID200 | Scleroderma, Diffuse | 9 | 2019-01-01 | 2020-06-20actual | — | 2024-11-19 |
| AMGN | Amgen | $229.9B | A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)NCT04478994results2024-04-19Number of Participants Experiencing a Treatment Emergent Adverse Event (TEAE) Through Week 24 | Phase 1 | Terminatedsponsor's stated reason: Poor enrollment | Biological: TEPEZZA · Other: Placebo | Diffuse Cutaneous Systemic Sclerosis | 3 | 2021-11-17 | 2022-11-29actual | — | 2024-06-28 |
| UTHR | United Therapeutics | $22.2B | Open-Label Study of Oral Treprostinil in Digital UlcersNCT00848107results2014-02-07Net Ulcer Burden- Mean Change From Time of Study Entry for Each Scheduled Visit Assessment | Phase 2 | Terminatedsponsor's stated reason: The TDE-DU-202 extension study was discontinued after the randomized, placebo-controlled TDE-DU-201 study did not meet its primary efficacy objective. | Drug: treprostinil diethanolamine | Systemic Sclerosis | 115 | Sep 2009 | Sep 2011actual | — | 2024-06-18 |
| UTHR | United Therapeutics | $22.2B | Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil DiethanolamineNCT00775463results2014-03-17Net Ulcer Burden | Phase 2 | Completed | Drug: treprostinil diethanolamine, placebo | Systemic Sclerosis, Scleroderma | 148 | May 2009 | Mar 2011actual | — | 2023-12-28 |
| SNY | Sanofi | — | Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic SclerosisNCT02921971results2022-02-02Change From Baseline in Modified Rodnan Skin Score to Week 24 | Phase 2 | Completed | Drug: SAR156597, Placebo | Systemic Sclerosis | 97 | 2016-12-21 | 2019-01-14actual | — | 2022-03-21 |
| CRBP | Corbus Pharmaceuticals Inc. | $195M | Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic SclerosisNCT02465437results2018-10-02Number of Participants With Treatment-emergent Adverse Events From Baseline at Day 113 | Phase 2 | Terminatedsponsor's stated reason: Sponsor terminated open-label extension | Drug: JBT-101, Placebo, Part B Open-Label Extension | Diffuse Cutaneous Systemic Sclerosis | 42 | Aug 2015 | Oct 2016actual | — | 2021-04-21 |
| CRBP | Corbus Pharmaceuticals Inc. | $195M | Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic SclerosisNCT03398837Efficacy of lenabasum compared to placebo for the American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis score. | Phase 3 | Terminatedsponsor's stated reason: Sponsor terminated open-label extension | Drug: Lenabasum 5 mg, Lenabasum 20 mg · Other: Placebo oral capsule | Diffuse Cutaneous Systemic Sclerosis | 365 | 2017-12-18 | 2020-05-27actual | — | 2021-03-29 |
| BMY | Bristol-Myers Squibb | $134.9B | A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)NCT02588625Part A - Change in modified Rodnan skin score (mRSS) | Phase 2 | Withdrawn | Drug: BMS-986020 · Other: Placebo | Scleroderma | 0 | Feb 2016 | Oct 2019 | — | 2016-07-22 |
| SNY | Sanofi | — | Proof of Biological Activity of SAR100842 in Systemic SclerosisNCT01651143Safety and tolerability during the 8 week treatment period (core part): Number of patients reporting adverse events | Phase 2 | Completed | Drug: SAR100842, Placebo (for SAR100842) | Systemic Sclerosis | 32 | Jan 2013 | Nov 2013actual | — | 2016-03-25 |
| BIIB | Biogen | $31.4B | Systemic Sclerosis Clinical and Biomarker StudyNCT02531009observationalChange in University of California at Los Angeles Scleroderma Clinical Trial Consortium GI Tract (UCLA-SCTC GIT) instrument score in participants with SSc | — | Withdrawn | — | Healthy, Systemic Sclerosis | 0 | Dec 2015 | Mar 2017 | — | 2015-11-02 |
| UTHR | United Therapeutics | $22.2B | Pharmacokinetics of Oral Treprostinil in Patients With Systemic SclerosisNCT00848939Cohort 1: treprostinil pharmacokinetics in patients with systemic sclerosis following single oral administration of a 1 mg treprostinil diethanolamine SR dose. | Phase 1 | Completed | Drug: treprostinil diethanolamine, treprostinil diethanolamine | Systemic Sclerosis | 28 | Dec 2008 | Jan 2010actual | — | 2012-10-23 |
| BMY | Bristol-Myers Squibb | $134.9B | Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary FibrosisNCT00764309results2012-02-29Number of Participants Who Died, Experienced Serious Adverse Events (SAEs), or Adverse Events (AEs) | Phase 1/2 | Completed | Drug: dasatinib | Scleroderma | 47 | Jan 2009 | Jun 2010actual | — | 2012-02-29 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Systemic Sclerosis is matched — 5 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Systemic Sclerosis
- Scleroderma
- Diffuse Cutaneous Systemic Sclerosis
- Systemic Sclerosis (SSc)
- Scleroderma, Diffuse
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Systemic Sclerosis” (a text search, wider than this page)